Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function

Journal of Neurochemistry

Volumn 72, Issue 3, 1999, Pages 1117-1124

  Fryer, John D ^a   Lukas, Ronald J ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Acetylcholine; Depression; Fluoxetine; Nefazodone; Nicotinic receptor; Paroxetine; Sertraline; Venlafaxin e

Indexed keywords

ANTIDEPRESSANT AGENT; ION CHANNEL; NEFAZODONE; NICOTINIC RECEPTOR; PAROXETINE; RECEPTOR SUBTYPE; SERTRALINE; VENLAFAXINE;

ARTICLE; BRAIN; DEPRESSION; DOSE RESPONSE; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BINDING, COMPETITIVE; CELL LINE; CHICK EMBRYO; HUMANS; LIGANDS; NICOTINIC ANTAGONISTS; POWDERS; RECEPTORS, NICOTINIC; RUBIDIUM RADIOISOTOPES; TABLETS;

EID: 0033014178     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1999.0721117.x     Document Type: Article

References (45)

1. Albuquerque E. X., Tsai M. C., Aronstam R. S., Eldefrawi A. T., and Eldefrawi M. E. (1980) Sites of action of phencyclidine. II. Interaction with the ionic channel of the nicotinic receptor. Mol. Pharmacol. 18, 167-178.
2. Anda R. E., Williamson D. F., Escobedo L. G., Mast E. E., Giovino G. A., and Remington P. I. (1990) Depression and the dynamics of smoking: a national perspective. JAMA 264, 1541-1545.
3. Andrews J. M. and Nemeroff C. B. (1994) Contemporary management of depression. Am. J. Med. 97, 24S-32S.
4. 3H]imipramine in bovine adrenal medullary cells. J. Pharmacol. Exp. Ther. 243, 342-348.
5. Bencherif M. and Lukas R. J. (1993) Cytochalasin modulation of nicotinic cholinergic receptor expression and muscarinic receptor function in human TE67I/RD cells: a possible functional role of the cytoskeleton. J. Neurochem. 61, 852-864.
6. Bencherif M., Eisenhour C. M., Prince R. J., Lippiello P. M., and Lukas R. J. (1995) The "calcium antagonist" TMB-8 [3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester] is a potent, non-competitive, functional antagonist at diverse nicotinic acetylcholine receptor subtypes. J. Pharmacol. Exp. Ther. 275, 1418-1426.
7. Catterson M. L. and Preskorn S. H. (1996) Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance. Pharmacol. Toxicol. 78, 203-208.
8. Conroy W. G. and Berg D. K. (1995) Neurons can maintain multiple classes of nicotinic acetylcholine receptors distinguished by different subunit compositions. J. Biol. Chem. 270, 4424-4431.
9. DeVane C. L. (1992) Pharmacokinetics of the selective serotonin reuptake inhibitors. J. Clin. Psychiatry 53(Suppl), 13-20.
10. DeVane C. L. (1994) Pharmacokinetics of the newer antidepressants: clinical relevance. Am. J. Med. 97, 13S-23S.
11. Eldefrawi M. E., Warnick J. E., Schofield G. G., Albuquerque E. X., and Eldefrawi A. T. (1981) Interaction of imipramine with the ionic channel of the acetylcholine receptor of motor endplate and electric organ. Biochem. Pharmacol. 30, 1391-1394.
12. 3H]Phencyclidine interactions with the nicotinic acetylcholine receptor channel and its inhibition by psychotropic, antipsychotic, opiate, antidepressant, antibiotic, antiviral, and antiarrhythmic drugs. Mol. Pharmacol. 22, 72-81.
13. Fryer J. D. and Lukas R. J. (1998) Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. Soc. Neurosci. Abstr. 24, 84.
14. Fryer J. D. and Lukas R. J. (1999) Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J. Pharmacol. Exp. Ther. (in press).
15. 3H]norepinephrine from fetal rat locus coeruleus cells in culture. J. Neurochem. 70, 663-670.
16. Galzi J.-L. and Changeux J.-P. (1994) Ligand-gated ion channels as unconventional allosteric proteins. Curr. Opin. Struct. Biol. 4, 554-565.
17. Garcia-Colunga J., Awad J. N., and Miledi R. (1997) Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac). Proc. Natl. Acad. Sci. USA 94, 2041-2044.
18. Glassman A. H., Helzer J. E., Covey L. S., Cottler L. B., Stetner F., Tipp J. E., and Johnson J. (1990) Smoking, smoking cessation, and major depression. JAMA 264, 1546-1549.
19. Goldner F. M., Dineley K. T., and Patrick J. W. (1997) Immunohistochemical localization of the nicotinic acetylcholine receptor subunit alpha6 to dopaminergic neurons in the substantia nigra and ventral tegmental area. Neuroreport 8, 2739-2742.
20. Hennings E. C., Kiss J. P., and Vizi E. S. (1997) Nicotinic acetylcholine receptor antagonist effect of fluoxetine in rat hippocampal slices. Brain Res. 759, 292-294.
21. Karson C. N., Newton J. E., Livingston R., Jolly J. B., Cooper T. B., Sprigg J., and Komoroski R. A. (1993) Human brain fluoxetine concentrations. J. Neuropsychiatry Clin. Neurosci. 5, 322-329.
22. Komorski R. A., Newton J. E., Cardwell D., Sprigg J., Pearce J., and Karson C. N. (1994) In vivo 19F spin relaxation and localized spectroscopy of fluoxetine in human brain. Magn. Reson. Med. 31, 204-211.
23. Kornhuber J., Retz W., and Riederer P. (1995) Slow accumulation of psychotropic substances in the human brain. Relationship to therapeutic latency of neuroleptic and antidepressant drugs? J. Neural Transm. Suppl. 46, 315-323.
24. Le Novere N., Zoli M., and Changeux J.-P. (1996) Neuronal nicotinic receptor α6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. Eur. J. Neurol. 8, 2428-2439.
25. Lindstrom J. (1996) Neuronal nicotinic acetylcholine receptors, in Ion Channels Vol. 4 (Narahashi T., ed), pp. 377-450. Plenum Press, New York.
26. Lukas R. J. (1984) Properties of curaremimetic neruotoxin binding sites in the rat central nervous system. Biochemistry 23, 1152-1160.
27. Lukas R. J. (1986) Immunochemical and pharmacological distinctions between curaremimetic neurotoxin binding sites of central, autonomic, and peripheral origin. Proc. Natl. Acad Sci. USA 83, 5741-5745.
28. Lukas R. J. (1989) Pharmacological distinctions between functional nicotinic acetylcholine receptors on the PC12 rat pheochromocytoma and the TE671 human medulloblastoma. J. Pharmacol. Exp. Ther. 251, 175-182.
29. 3H]acetylcholine binding sites. J. Pharmacol. Exp. Ther. 253, 51-57.
30. Lukas R. J. (1993) Expression of ganglia-type nicotinic acetylcholine receptors and nicotinic ligand binding sites by cells of the IMR-32 human neuroblastoma clonal line. J. Pharmacol. Exp. Ther. 5, 294-302.
31. Lukas R. J. (1998) Neuronal nicolinic acetylcholine receptors, in The Nicotinic Acetylcholine Receptor: Current Views and Future Trends (Barrantes F. J., ed), pp. 145-173. Springer Verlag, Heidelberg/Berlin.
32. Lukas R. J. and Bencherif M. (1992) Heterogeneity and regulation of nicotinic acetylcholine receptors. Intl. Rev. Neurobiol. 34, 25-131.
33. Lukas R. J., Lucero L., Eisenhour C. M., and Puchacz E. (1996) Function of transgenic nicotinic acetylcholine receptors expressed in human cells stably transfected with α7 subunits. Soc. Neurosci. Abstr. 22, 1268.
34. Maggi L., Palma E., Miledi R., and Eusebi F. (1998) Effects of fluoxetine on wild and mutant neuronal alpha 7 nicotinic receptors. Mol. Psychiatry 3, 305-355.
35. Peng J.-H., Lucero L., Fryer J., Herl J., Leonard S. S., and Lukas R. J. (1998) Inducible, heterologous expression of human α7-nicotinic acetylcholine receptors in a native nicotinic receptor-null human clonal line. Naunyn Schmiedehergs Arch. Pharmacol. 358 (Suppl. 2), R577.
36. Puchacz E., Buisson B., Bertrand D., and Lukas R. J. (1994) Functional expression of nicotinic acetylcholine receptors containing rat alpha 7 subunits in human SH-SY5Y neuroblastoma cells. FEBS Lett. 354, 155-159.
37. Puchacz E., Galzi J.-L., Buisson B., Bertrand D., Changeux J.-P., and Lukas R. J. (1995) Properties of transgenic nicotinic acetylcholine receptors stably expressed in human cells as homooligomers of wild-type or mutant rat or chick α7 subunits. Soc. Neurosci. Abstr. 21, 1335.
38. Rana B., McMorn S. O., Reeve H. L., Wyatt C. N., Vaughan P. F., and Peers C. (1993) Inhibition of neuronal nicotinic acetylcholine receptors by imipramineand desipramine. Eur. J. Pharmacol. 250, 247-251.
39. Renshaw P. F., Guimaraes A. R., Fava M., Rosenbaum J. F., Pearlman J. D., Flood J. G., Puopolo P. R., Clancy K., and Gonzalez R. G. (1992) Accumulation of fluoxeline and norfluoxeline in human brain during therapeutic administration. Am. J. Psychiatry 149, 1592-1594.
40. Ribeiro E. B., Bettiker R. L., Bogdanov M., and Wurtman R. J. (1993) Effects of systemic nicotine on serotonin release in rat brain. Brain Res. 621, 311-318.
41. Sacaan A. I., Dunlop J. L., and Lloyd G. K. (1995) Pharmacological characterization of neuronal acetylcholine gated ion channel receptor-mediated hippocampal norepinephrine and striatal dopamine release from rat brain slices. J. Pharmacol. Exp. Ther. 274, 224-230.
42. Schmalzing G. (1988) The role of a transmembrane pH gradient in uptake and release of imipramine and haloperidol in synaptosomes. Mol. Pharmacol. 34, 888-895.
43. Schofield G. G., Witkop B., Warnick J. E., and Albuquerque E. X. (1981) Differentiation of the open and closed states of the ionic channels of nicotinic acetylcholine receptors by tricyclic antidepressants. Proc. Nail. Acad. Sci. USA 78, 5240-5244.
44. Stoudemire A. (1995) Expanding psychopharmacologic treatment options for the depressed medical patient. Psychosomatics 36, S19-S26.
45. Wada E., Wada K., Boulter J., Deneris E., Heinemann S., Patrick J., and Swanson L. W. (1989) Distribution of alpha2, alpha3, alpha4, and beta2 neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. J. Comp. Neurol. 284, 314-335.